Clinical Trials Browser

Phase 3 × afuresertib × 90 days × Clear all

NCT04851613 2026-04-02

Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Phase 3 Active not recruiting

Breast Neoplasms